However, the distribution and pattern of catalase-positive cells are different between the groups of BLM + Nintedanib and BLM + Pirfenidone, resulting from the diverse mechanisms to treat lung fibrosis of these two medications. The gene discussed is CAT; the disease is pulmonary fibrosis.